{"id":748050,"date":"2023-04-17T08:25:21","date_gmt":"2023-04-17T12:25:21","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/"},"modified":"2023-04-17T08:25:21","modified_gmt":"2023-04-17T12:25:21","slug":"enlivex-appoints-andrew-singer-to-its-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/","title":{"rendered":"Enlivex Appoints Andrew Singer to its Board of Directors"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <i>Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy<\/i>\n        <\/li>\n<li>\n          <i>Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets<\/i>\n        <\/li>\n<li>\n          <i>Led financing, partnering and M&amp;A biopharmaceutical transactions in excess of $13 billion<\/i>\n        <\/li>\n<\/ul>\n<p>\n        <strong>Nes-Ziona, Israel, April  17, 2023  (GLOBE NEWSWIRE) &#8212; <\/strong> Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career.<\/p>\n<p>\u201cIt is an honor to join the Enlivex Board at this important juncture in the Company\u2019s evolution,\u201d said Mr. Singer. \u201cEnlivex has developed a novel and exciting approach to reprogramming macrophages, with potential application across a range of autoimmune, inflammatory and oncology indications. I look forward to collaborating with my fellow Board members and the Company\u2019s management team as we work to advance Allocetra\u2019s clinical development. With a broad technology platform underpinned by strong science and multiple clinical programs, I believe that Enlivex is well positioned for sustained success.\u201d<\/p>\n<p>Shai Novik, Executive Chairman of the Board of Enlivex, stated, \u201cAs a senior investment banker in the United States for several decades, Andrew has helped many successful biotech companies craft and execute their corporate and financial strategy.\u00a0 Additionally, Andrew has hands-on experience as a public biotech company executive, leading finance and business development, having executed and managed public financings as well as partnerships with some of the world\u2019s leading pharmaceutical companies. We believe that Andrew\u2019s extensive experience makes him an ideal fit for Enlivex\u2019s Board. We look forward to benefiting from his expert insights as we execute on our clinical and corporate strategy. It is my pleasure to welcome him to the Company as a board member.\u201d <\/p>\n<p>The Enlivex Board determined that Mr. Singer is an \u201cindependent director\u201d within the meaning of NASDAQ Listing Rule 5605(a)(2).<\/p>\n<p>\n        <b>ABOUT ALLOCETRA\u2122<\/b>\n      <\/p>\n<p>Allocetra\u2122\u00a0\u00a0is being developed as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, Allocetra\u2122\u00a0has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as \u201dunmet medical needs\u201d, as a stand-alone therapy or in combination with leading therapeutic agents.<\/p>\n<p>\n        <b>ABOUT ENLIVEX<\/b>\n      <\/p>\n<p>Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra\u2122, a universal, off-the-shelf cell therapy designed to\u00a0reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening conditions. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2kKy7z9N3uup3g1Dw4_NOE0LeJqgjB4n-zoKUFH9JecqzStKw5Ye5h6XN2GADTp6dXGeVP-5CoGTuv58akw-tA==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/enlivex.com\/<\/u><\/a>. <\/p>\n<p>\n        <i>Safe Harbor Statement:\u00a0 This press release contains forward-looking statements, which may be identified by words such as \u201cexpects,\u201d \u201cplans,\u201d \u201cprojects,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201canticipates,\u201d \u201cbelieves,\u201d \u201cshould,\u201d \u201cwould\u201d, \u201ccould,\u201d \u201cintends,\u201d \u201cestimates,\u201d \u201csuggests,\u201d \u201chas the potential to\u201d and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA<sup>TM<\/sup>\u00a0programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.\u00a0 Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect\u00a0Enlivex\u2019s\u00a0business and prospects, including the risks that\u00a0Enlivex\u00a0may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and\/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA<sup>TM<\/sup>\u00a0product line could also be affected by\u00a0a number of\u00a0other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.\u00a0 In addition to the risk factors described above, investors should consider the economic, competitive, governmental,\u00a0technological\u00a0and other factors discussed in\u00a0Enlivex\u2019s\u00a0filings with the Securities and Exchange Commission, including in the Company\u2019s most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission.\u00a0 The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.<\/i>\n      <\/p>\n<p>\n        <br \/>\n        <b>ENLIVEX CONTACT<\/b>\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n<p>Shachar Shlosberger, CFO\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/> Enlivex Therapeutics, Ltd.\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=yjHoF5iOzsDIfiucx594N47IOanUPzlswJ97ZhozzqaHQb_2g3NZ9Z6GivZqBSr6tvrXmWo00PaqyGt5oslRSDY8P2ErSDiP_aac6zI2Zic=\" rel=\"nofollow noopener\" target=\"_blank\"><u>shachar@enlivexpharm.com<\/u><\/a><\/p>\n<p>\n        <b>INVESTOR RELATIONS CONTACT<\/b><br \/>\n        \n      <\/p>\n<p>Eric Ribner<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BaKbBeAHUqQzTm8KWV3SSeQSGKufQNtxHfPtpBZKhQwNorMOoVIVGrpQB6AEj21LzjI0_tqvvFYqO94Gtv3NeMxS_a1QjBAbb0mmlvEuGgk=\" rel=\"nofollow noopener\" target=\"_blank\"><u>eric@lifesciadvisors.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZGIzZTMzOTEtYmNlNC00MWZhLWI2OGQtZjcyYzY2NzEwZGVkLTUwMDA2NTE3NA==\/tiny\/Enlivex-Therapeutics-Ltd.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets Led financing, partnering and M&amp;A biopharmaceutical transactions in excess of $13 billion Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career. \u201cIt is an honor to join the Enlivex &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Enlivex Appoints Andrew Singer to its Board of Directors&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-748050","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets Led financing, partnering and M&amp;A biopharmaceutical transactions in excess of $13 billion Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career. \u201cIt is an honor to join the Enlivex &hellip; Continue reading &quot;Enlivex Appoints Andrew Singer to its Board of Directors&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T12:25:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Enlivex Appoints Andrew Singer to its Board of Directors\",\"datePublished\":\"2023-04-17T12:25:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/\"},\"wordCount\":888,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/\",\"name\":\"Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\",\"datePublished\":\"2023-04-17T12:25:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/enlivex-appoints-andrew-singer-to-its-board-of-directors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enlivex Appoints Andrew Singer to its Board of Directors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/","og_locale":"en_US","og_type":"article","og_title":"Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk","og_description":"Mr. Singer brings over 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy Former EVP and CFO of Epizyme and Senior Biotech Investment Banker at Credit Suisse, Wells Fargo Securities and RBC Capital Markets Led financing, partnering and M&amp;A biopharmaceutical transactions in excess of $13 billion Nes-Ziona, Israel, April 17, 2023 (GLOBE NEWSWIRE) &#8212; Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the \u201cCompany\u201d), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Andrew Singer to its Board of Directors. Mr. Singer brings more than 25 years of experience in biotechnology, corporate finance, mergers and acquisitions, and business strategy from his extensive investment banking and executive management career. \u201cIt is an honor to join the Enlivex &hellip; Continue reading \"Enlivex Appoints Andrew Singer to its Board of Directors\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-17T12:25:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Enlivex Appoints Andrew Singer to its Board of Directors","datePublished":"2023-04-17T12:25:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/"},"wordCount":888,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/","name":"Enlivex Appoints Andrew Singer to its Board of Directors - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==","datePublished":"2023-04-17T12:25:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwODY4MSM1NTI4NTc3IzUwMDA2NTE3NA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/enlivex-appoints-andrew-singer-to-its-board-of-directors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Enlivex Appoints Andrew Singer to its Board of Directors"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=748050"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/748050\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=748050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=748050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=748050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}